TomoTherapy, a radiation therapy system developer, has filed a registration statement with the Securities and Exchange Commission for a proposed secondary offering of 8.5 million shares of its common stock solely by certain selling shareholders.
The selling shareholders will grant the underwriters an option to acquire an additional 1.275 millionshares to cover over-allotments, according to the Madison, Wis.-based TomoTherapy.
The developer said it will not receive any proceeds from the sale of the shares, and will pay the expenses of the offering, excluding underwriting discounts.
Merrill Lynch is acting as sole book-running manager. Piper Jaffray, Thomas Weisel Partners, Robert W. Baird and William Blair are acting as co-managers for the offering.